Search | Clinical Trials Finder

Conditions: Atopic Dermatitis
Interventions: LEO 138559, LEO 138559 Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis
Interventions: GHZ339, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 18 more

Conditions: Eczema
Interventions: Topical B12 0.07%; Drug
Lead sponsor: Spartanburg Regional Healthcare System; Other
Eligibility: 6 Months to 18 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Atopic Dermatitis
Interventions: OPA-15406, Tacrolimus, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more

Conditions: Atopic Dermatitis
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 60
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: Asimadoline, Placebo; Drug
Lead sponsor: Tioga Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more

Conditions: Mild to Moderate Atopic Dermatitis
Interventions: Online Treatment response, EUCRISA; Behavioral · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years to 64 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atopic Dermatitis
Interventions: hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Atopic Dermatitis
Interventions: RPT193, Placebo; Drug · Other
Lead sponsor: RAPT Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 45 more

Conditions: Xerosis, Xerosis Cutis, Dry Skin; Eczema
Interventions: virgin coconut oil, virgin jojoba oil, virgin almond oil, white petrolatum ointment; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Tucson, Arizona • Sacramento, California

Conditions: Dermatitis, Atopic
Interventions: Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 368 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Atopic Dermatitis
Interventions: BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo; Drug
Lead sponsor: Brexogen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions: ATTO-1310, ATTO-1310 Placebo; Drug
Lead sponsor: Attovia Therapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Encinitas, California • Rocklin, California • Sacramento, California + 7 more

Conditions: Smallpox, Atopic Dermatitis
Interventions: MVA (smallpox vaccine); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Portland, Oregon • Austin, Texas

Conditions: Atopic Dermatitis
Interventions: Sponsor Test Products; Other
Lead sponsor: Burt's Bees Inc.; Industry
Eligibility: 6 Months to 7 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Atopic Dermatitis
Interventions: Tencel Therapeutic Garments, Cotton Therapeutic Garments; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Months to 6 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions: NAET Procedures; Procedure
Lead sponsor: Nambudripad's Allergy Research Foundation; Other
Eligibility: 2 Years to 78 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Buena Park, California

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more

Conditions: Atopic Dermatitis
Interventions: SAR444656 (KT-474), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Scottsdale, Arizona • Boynton Beach, Florida • Doral, Florida + 6 more

Conditions: Atopic Dermatitis
Interventions: IDP-124 Lotion, IDP-124 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fremont, California

Conditions: Atopic Dermatitis
Interventions: EDP1815; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 19 more

Conditions: Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more

Search by objective public record fields.

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Eucrisa for Atopic Dermatitis

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer

Tencel vs. Standard Cotton Therapeutic Garments as an Adjunct Treatment for Moderate to Severe Atopic Dermatitis in Children

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy